Download Cancer Control and Population Sciences Program HCI Annual

Cancer Control and Population Sciences Program
HCI Annual Progress Reporting
Kathleen Mooney, PhD, RN, and Sean Tavtigian, PhD, Program Co-Leaders
PROGRAM GOALS AND CHARACTERISTICS
Themes, emphases, and goals of our program remain the same as described in HCI’s 2014 CCSG competitive
application and site visit:
1. Translational Cancer Predisposition Genetics
2. Cancer Behavioral and Outcomes Research
A number of CCPS members cross both themes, and our studies and collaborations utilize a variety of
methods, including molecular and genetic laboratory, bioinformatics, population science, and clinical research
approaches.
CCPS 2015 PROGRAM CHARACTERISTICS
#
MEMBERS
Total
Full
Associate
Departments
Schools/Colleges
Members with Funding
Full Members with Funding*
Full Members with PR Funding*
DEGREES
MD
MD/PhD
PhD
RANK
Assistant Professor
Associate Professor
Professor
Visiting Instructor
PUBLICATIONS
Total
High-impact
Intra-Program
Inter-Program
HCI Collaborative
%
#
49
29
20
18
8
32
28
23
100%
59%
41%
11
1
37
22%
2%
76%
15
9
24
1
31%
18%
49%
2%
181
49
47
30
70
100%
27%
26%
17%
39%
65%
97%
79%
FUNDING (TC)
NCI
Other NIH
Other PR
Total PR
Industry
Other non-PR
Total Non-PR
Grand Total
CLINICAL TRIALS (2014)
Number of Trials
All trials**
Investigator-Initiated (IIT)
Treatment
Number of Accruals
All trials**
Investigator-Initiated (IIT)
Treatment
Accruals by Funding Source
NCTN
Ext Peer-Reviewed
Institutional
Industry
Total
$(%)
30
9
5
44
11
18
29
73
5,345,749
2,840,177
169,094
8,355,020
803,723
1,187,715
1,991,438
10,346,458
68
33
101
Total
36
1210
2348
179
3773
3773
2897
0
Treatment
0
0
0
0
0
* % of full members; **All trials: IIT, treatment, plus other. Number of trials: trials open to accrual in the given calendar year.
Program Leadership
Kathleen Mooney, PhD, RN, and Sean Tavtigian, PhD, continue to lead the CCPS program, having been
appointed to this leadership position in May 2013. Both also continue active programs of funded research. Dr.
Mooney is a well-known leader in the cancer control field of palliative care, remote telehealth symptom
management, and patient reported outcomes. She is the PI on a NCI-funded P01 award; a renewal of that
project is currently under review. Dr. Mooney recently received a favorable review (15 impact score, 2nd
percentile) on a new NCI R01 (Mooney, PI) that extends her work on remote telehealth symptom management.
Dr. Tavtigian is an internationally recognized molecular geneticist whose research focuses on identification and
further evaluation of cancer susceptibility genes and methods of evaluating unclassified variants of cancer
susceptibility genes. He is currently joint-PI on three NCI R01s and joint-PI on an NCI PPG. He recently
submitted an Outstanding Investigator (R35) application, as well as a R01, and plans a new PPG submission
for January 2016.
Program Membership
The CCPS program has benefitted from new HCI Senior Leadership appointments, with the arrivals of Cornelia
Ulrich, PhD, in late 2014, to the position of Senior Director of Population Sciences and Ana Maria Lopez, MD,
in 2015, to the position of Director of Cancer Health Equity. Both are CCPS members. Dr. Ulrich is an
internationally known molecular epidemiologist whose research focuses on lifestyle and biologic factors in
cancer prevention and cancer prognosis. She came to HCI from the German Cancer Research Center and
National Center for Tumor Diseases, where she was Director, as well as Head of the Department of Preventive
Oncology. Dr. Lopez is a medical oncologist. In addition to her HCI position as Director of Cancer Health
Equity, she is also Associate Vice President for Health Equity and Inclusion for University of Utah Health
Sciences. Her research interests include integrative oncology, cancer health disparities, and innovative uses of
telemedicine. Dr. Lopez came from the University of Arizona where she was a professor of medicine and
directed the telemedicine program.
Since the 2014 competitive renewal of HCI’s CCSG, we have added 11 new members, including six associate
and five full members. We have continued to grow our membership through both new faculty hires and
recruitment of current faculty. New members include the following: HCI and the University of Utah
Communications Department strategically recruited Kimberly Kaphingst, ScD, from Washington University
School of Medicine in St. Louis. Dr. Kaphingst's research interests are in health literacy, cancer
communication, and the communication of genetic and genomic information. She is PI on a NCI-funded R01
study that is examining communication preferences for whole genome sequencing results among women
diagnosed with breast cancer at age 40 or younger. Among internally recruited new CCPS members is Gary
W. Donaldson, PhD, a professor in the Department of Anesthesiology since 2001. Previously, he was at the
University of Washington Fred Hutchinson Cancer Research Center, where he still holds an affiliate
investigator position. Dr. Donaldson’s research focuses on statistical methodologies related to quality-of-life
research in the fields of cancer and acute and chronic pain. CCPS also recruited two professors from the
department of Human Genetics, Gabor Marth, PhD and Mark Yandell, PhD, to its membership.
We are pleased with the progress and success of several of our associate members. Yelena Wu, PhD, a child
psychologist who was recruited to the University of Utah and CCPS two years ago was awarded a NCI-funded
K07 academic career award for her work on communicating genetic risk information to children. Jakob Jensen,
PhD, an Associate Professor in the Communications Department and also recruited two years ago, was
awarded a 2015 New Innovator Grant from NIH for his research program in skin cancer control. Deborah
Neklason, PhD, a genetic epidemiologist, has a pending NCI R21 grant on carcinoid tumors that reviewed at
the 4th percentile and Deanna Kepka, PhD, has been project director of a P30 CCSG administrative
supplement grant focused on developing collaborations across several states to increase HPV vaccine uptake.
She also has a pending NCI R03 application that is currently being processed. We continue to mentor and
work closely with our CCPS early stage investigators.
2015 KEY SCIENTIFIC ACCOMPLISHMENTS
Theme 1: Translational Cancer Predisposition Genetics
Familiality of less-common cancers
Ken Boucher, PhD (CCPS), Randall Burt, MD (CCPS), Saundra Buys, MD (CCPS), Lisa Cannon-Albright, PhD
(CCPS), Karen Curtin, PhD (CCPS), Heidi Hansen, PhD (CCPS), Mia Hashibe, PhD (CCPS), Will Lowrance,
MD (CCPS), Deborah Neklason, PhD (CCPS), Jewel Samadder, MD (CCPS), Ken Smith, PhD (CCPS),
Cornelia Ulrich, PhD (CCPS), Neeraj Agarwal, MD (ET), and Wallace Akerley, MD
Over the years, the Utah Population Database (UPDB) has been used for studies of site-specific cancer
familiality, susceptibility gene discovery, and, once genes have been identified, studies of tumor spectrum and
penetrance. Most of the headline results have come from the relatively common cancers for which high-risk
susceptibility genes have been found, principally breast, colorectal, and ovarian cancer. This past year, CCPS
members Ken Boucher, PhD, Randall Burt, MD, Saundra Buys, MD, Lisa Cannon-Albright, PhD, Karen
Curtin, PhD, Heidi Hansen, PhD, Mia Hashibe, PhD, Will Lowrance, MD, Deborah Neklason, PhD, Jewel
Samadder, MD, Ken Smith, PhD, and Cornelia Ulrich, PhD, teamed up in various combinations, along with
Neeraj Agarwal, MD (ET), and Wallace Akerley, MD (ET), to study the familiality of carcinoid cancer, lung
cancer in non-smokers, prostate cancer, and carcinoma of unknown primary.
Supported by a CCPS pilot grant, Deborah Neklason, PhD (CCPS) and team used UPDB data to examine the
familiality of neuroendocrine tumors of the small intestine (carcinoid tumors). They found that siblings have a
13.4-fold relative risk, and parents have a 6.5-fold relative risk, suggesting both genetic and environmental
influences. The risk extends out to 3rd degree relatives, who have a 2.3-fold relative risk. Close relatives of
carcinoid cancers were also at increased risk of colon, bladder, non-Hodgkin lymphoma, melanoma, and
prostate cancers (Neklason et al., Endocr Relat Cancer, 2016). This work led to an NCI R21 scoring 4th
percentile.
Also using UPDB data, Drs. Akerley, Hashibe, and Cannon-Albright examined the familiality of lung cancer
among both smokers and non-smokers. While both subsets showed elevated relative risks for close relatives,
only the non-smoking-related subset of cases showed significant excess relatedness when close relationships
were ignored (Carr et al., Thorax, 2015). This latter result provides evidence for a genetic contribution from
moderate to high-risk susceptibility genes to lung cancer susceptibility.
Carcinoma of Unknown Primary (CUP) accounts for 3-5% of all cancers, but familial clustering of this
constellation of tumors has not been examined. From analyses of UPDB data, Dr. Samadder and team found
that first-degree relatives of CUP cases had a 1.35-fold increased risk of CUP themselves, as well as 1.2-fold
to 1.4-fold increased risk of lung cancer, pancreatic cancer, myeloma, and non-Hodgkin lymphoma. The
constellation of site-specific tumors over-represented among the relatives of CUP-cases may suggest the sites
of origin of a large fraction of CUP tumors (Samadder et al., JAMA Oncology, 2015).
Carr SR, Akerley W (ET), Hashibe M (CCPS), Cannon-Albright LA (CCPS) Evidence for a genetical
contribution to non-smoking-related lung cancer. Thorax 2015 70:1033-9
Neklason D (CCPS), VanDerslice J, Curtin K (CCPS), Cannon-Albright LA (CCPS) Evidence for a heritable
contribution to neuroendocrine tumors of the small intestine. Endocr Relat Cancer 2016 23:93-100.
Samadder NJ (CCPS), Smith KR (CCPS), Hanson H, Pimentel R, Wong J, Boucher K (CCPS), Akerley W
(ET), Gilcrease G, Ulrich CM (CCPS), Burt RW (CCPS), Curtin K (CCPS). Familial Risk in Patients With
Carcinoma of Unknown Primary. JAMA Oncol. 2015 17:1-7.
Intersection of Themes 1 and 2: Influence of Genetics on Behavior and Outcomes
Reducing risk of melanoma: towards genetic counseling for childhood carriers of CDKN2a (p16)
mutations
Lisa Cannon-Albright, PhD (CCPS) and David Goldgar, PhD (CCPS)
In 1994, CCPS members Dr. Cannon-Albright and David Goldgar, PhD, used UPDB-derived pedigrees to
demonstrate that CDKN2A (p16) is an important melanoma susceptibility gene. At that time, mutation
screening of CDKN2A in melanoma cell lines revealed an excess of somatic variants that were likely to be the
consequence of UV-induced thymidine dimers, pointing towards a role for sunburn in the development of
melanoma in mutation carriers.
Given the suspected etiology of early life sunburns in the development of melanoma, it is important to develop
methods to encourage healthy sun behaviors in children who carry these mutations. However, there has been
no research that examines individuals’ discussions about melanoma preventive behaviors with children and
grandchildren after melanoma genetic testing.
With CCPS pilot funding, program members Drs. Wu, Lisa Aspinwall, PhD, and Sancy Leachman, MD, as
well as Genetic Counseling Shared Resource Leader, Wendy Kohlmann, examined individuals’ intentions to
discuss melanoma preventive behaviors with children and grandchildren following p16 genetic test reporting
and counseling, as well as whether individuals followed through on these intentions (Wu et al., J Community
Genet 2015). There were substantial proportions of participants who reported an intention to increase
discussion of healthy sun behaviors with offspring, but who reported discussing preventive behaviors
infrequently at one and six months. p16 carriers reported more frequent overall discussion of screening and
risk behaviors compared with non-carriers. For both carriers and non-carriers, the frequency of discussion of
preventive behaviors with children and grandchildren decreased significantly over time (from the time of
genetic test reporting and counseling to six months post-genetic test reporting). Their results indicate that
genetic test reporting and individualized genetic counseling alone do not appear to sustain individuals’
discussions about preventive behaviors for a hereditary cancer with their offspring who are at risk for the
illness. Individuals who receive melanoma genetic testing could benefit from additional support focused on
ongoing discussions with offspring about establishing lifelong healthy sun habits.
This year, Dr. Wu received a K07 award to continue research towards translational approaches to melanoma
prevention in children at high genetic risk in other areas of genetic susceptibility, for example, inherited
mutations in DNA homologous recombination repair genes, where childhood and adolescent exposures may
interact with inherited mutations to dramatically increase cancer risks many years later.
Wu YP (CCPS), Aspinwall LG (CCPS), Michaelis TC, Stump T, Kohlmann WG, Leachman SA (CCPS)
Discussion of photoprotection, screening, and risk behaviors with children and grandchildren after melanoma
genetic testing. J Community Genet 2016 7:21-31.
Theme 2: Cancer Behavioral and Outcomes Research
Home hospice cancer care
Lee Ellington, PhD (CCPS), Margaret Clayton, PhD (CCPS), and Maija Reblin, PhD (CCPS)
Funded by an NCI behavioral Program Project Grant, CCPS members Lee Ellington, PhD, Margaret
Clayton, PhD, and Maija Reblin, PhD, have been studying the interaction between home hospice nurses and
family caregivers. Family caregivers are often at the frontline of symptom management for cancer patients in
home hospice. These caregivers need to take advice from hospice nurses, but also face distressing issues
during care and after bereavement.
Informational support—guiding family caregivers in knowing what to do—is often a key component of a home
hospice nurse’s job. It is extremely important that the nurses explain to the caregiver what they are likely to
encounter. In recorded and coded conversations between nurses and caregivers, the nurses most often
mentioned Informational, Esteem, Tangible, and, finally, Emotional support, but with little difference in the
frequency of each of these types of support. Thus, it appears that the nurses saw these types of support to be
needed in equal measure across the range of their caseloads. In contrast, the family caregivers most often
mentioned Tangible, followed by Informational and Emotional support, and least mentioned Esteem support.
This result suggests that the nurses could become more sensitive and adept at matching their interventions to
the caregiver’s needs (Reblin et al., Palliat Support Care, 2015).
An interesting observation from these studies was that during treatment of the terminally ill patient, the family
caregivers often report being so focused on their spouse/partner's needs that they rarely spoke with hospice
staff about their own personal needs and emotions. After the patient’s death, bereavement counseling
generally came in the form of generic pamphlets or phone calls from someone that they had not met during
prior interactions with hospice staff. This appears to be a missed opportunity for hospices to address the
family-oriented goals often described in their mission statements (Tabler et al., J Soc Work End Life Palliat
Care, 2015).
Looking forward, their team also conducted a methodological study designed to capture home hospice nursecaregiver communication, a highly understudied location and type of communication event. The study
developed example protocols encompassing data collection in the home environment, large-scale, multisite
secure data management, the development of theoretically-based communication coding, plus strategies to
prevent coder drift and thereby improve reliability of analyses (Reblin et al., Health Communication, 2015).
Very recently, Dr. Ellington received a score of 10.0 on an R01 application that extends this work in a new
direction.
Reblin M (CCPS), Cloyes KG, Carpenter J, Berry PH, Clayton MF(CCPS), Ellington L (CCPS) Social support
needs: Discordance between home hospice nurses and former family caregivers. Palliat Support Care 2015
13:465-72
Reblin, M(CCPS), Clayton, M (CCPS), John, K & Ellington, L (CCPS). Addressing methodological
challenges in large communication datasets: Collecting and coding longitudinal interactions in home hospice
cancer care. Health Communication 1-9.
Tabler J, Utz RL, Ellington L (CCPS), Reblin M (CCPS), Caserta M (CCPS), Clayton M (CCPS), Lund D.
Missed Opportunity: Hospice Care and the Family. J Soc Work End Life Palliat Care. 2015 11:224-43.
RESEARCH AND/OR INITIATIVES FOCUSED ON THE NEEDS OF HCI’S CATCHMENT AREA
CCPS members are cognizant of gaps in cancer control and population science research relevant to our large
catchment area, including disparities related to high risk (melanoma), poor utilization of screening and
preventive strategies (HPV vaccine uptake), ethnic disparities (Native American and Latino), and disparities in
care due to remote geography (rural/frontier residence). Examples include:
• Kathi Mooney, PhD—Improving palliative care for rural/frontier dwellers, through R01 and P01 projects
utilizing remote, automated monitoring and coaching related to poorly controlled treatment-related or
end-of-life symptoms
• Kathi Mooney, PhD, Lee Ellington, PhD, Margaret Clayton, PhD, and Mike Caserta, PhD—A pending
P01 renewal focused on palliative care outreach and testing of interventions that can be delivered
remotely, including to cancer patients and family caregivers living in rural/frontier communities
• Jakob Jensen, PhD—2015 NIH New Innovator Grant for research program in high-tech methods of
mole identification and monitoring
• Lisa Aspinwall, PhD, Yelena Wu, PhD—A R01 examining family outcomes of genetic testing for genes
associated with heightened melanoma risk
• Yelena Wu, PhD—A K07 related to genetic risk communication to children of melanoma genetic risk
families
• Deanna Kepka, PhD—HPV vaccine uptake studies of parental and provider barriers, as well as studies
focused on Latinos and immigrant workers. This work is funded, in part by a supplement to HCI’s P30
CCSG grant to build a multi-state coalition to increase vaccine uptake.
• Ana Maria Lopez, MD—The NCI Geographical Management of Cancer Health Disparities Program
(GMaP, funded by a supplement to the HCI CCSG) is a systematic and comprehensive approach to
facilitating collaboration, cooperation, information- and resource-sharing, and capacity-building among
cancer health disparities researchers, trainees, outreach workers, and organizations, with the key goal
of advancing cancer health disparities (CHD) research and training. In 2015, NCI named HCI as the
GMaP hub serving Idaho, Montana, Nevada, North Dakota, South Dakota, Utah and Wyoming. The
HCI GMaP hub will enhance regional capacity in communication/dissemination, recruitment/placement
and evaluation, along with offering support and efficient management of CHD research, training, and
outreach.
• Martha Slattery, PhD—HCI Staff Investigator; studies of gene-environment epidemiology among
individuals of Native American ancestry
SELECTED CCPS PUBLICATIONS YEAR 26
The journal articles listed below are selected from a total of 181Program-related publications. Publications
for dual members are reported in only one Program.
Reference
1.
Albright F, Stephenson RA, Agarwal N (ET), Teerlink CC, Lowrance WT (CCPS),
Farnham JM, Albright LA (CCPS) (2015) Prostate cancer risk prediction based on
complete prostate cancer family history. Prostate 75:390-8. PMCID: PMC4293302
2.
Amin Al Olama A, Benlloch S, Antoniou AC, Giles GG, Severi G, Neal DE, Hamdy
FC, Donovan JL, Muir K, Schleutker J, Henderson BE, Haiman CA, Schumacher FR,
Pashayan N, Pharoah PD, Ostrander EA, Stanford JL, Batra J, Clements JA,
Chambers SK, Weischer M, Nordestgaard BG, Ingles SA, Sorensen KD, Orntoft TF,
Park JY, Cybulski C, Maier C, Doerk T, Dickinson JL, Cannon-Albright L (CCPS),
Brenner H, Rebbeck TR, Zeigler-Johnson C, Habuchi T, Thibodeau SN, Cooney KA,
Chappuis PO, Hutter P, Kaneva RP, Foulkes WD, Zeegers MP, Lu YJ, Zhang HW,
Stephenson R, Cox A, Southey MC, Spurdle AB, FitzGerald L, Leongamornlert D,
Saunders E, Tymrakiewicz M, Guy M, Dadaev T, Little SJ, Govindasami K, Sawyer E,
Wilkinson R, Herkommer K, Hopper JL, Lophatonanon A, Rinckleb AE, Kote-Jarai Z,
Eeles RA, Easton DF (2015) Risk Analysis of Prostate Cancer in PRACTICAL, a
Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci.
Cancer Epidemiol Biomarkers Prev 24:1121-9. PMCID: PMC4491026
3.
Botkin JR, Rothwell E (CCPS), Anderson R, Stark LA, Mitchell J (2015) Public
attitudes regarding the use of electronic health information and residual clinical
tissues for research. J Community Genet 6:183. PMCID: PMC4356674
4.
Cheng TY, Makar KW, Neuhouser ML, Miller JW, Song X, Brown EC, Beresford SA,
Zheng Y, Poole EM, Galbraith RL, Duggan DJ, Habermann N, Bailey LB, Maneval
DR, Caudill MA, Toriola AT, Green R, Ulrich CM (CCPS) (2015) Folate-mediated
one-carbon metabolism genes and interactions with nutritional factors on colorectal
cancer risk: Women's Health Initiative Observational Study. Cancer 121:3684-91.
PMCID: PMC4592375
5.
Coghill AE, Shiels MS, Suneja G (CCPS), Engels EA (2015) Elevated CancerSpecific Mortality Among HIV-Infected Patients in the United States. J Clin Oncol
33:2376-83. PMCID: PMC4500831
6.
Contreras JL (CCPS) (2015) NIH's genomic data sharing policy: timing and tradeoffs.
Trends Genet 31:55-7
7.
Easton DF, Pharoah PD, Antoniou AC, Tischkowitz M, Tavtigian SV (CCPS),
Nathanson KL, Devilee P, Meindl A, Couch FJ, Southey M, Goldgar DE (CCPS),
Evans DG, Chenevix-Trench G, Rahman N, Robson M, Domchek SM, Foulkes WD
(2015) Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med
372:2243-57. PMCID: PMC4610139
8.
Hanson HA (CCPS), Smith KR (CCPS), Zimmer Z (2015) Reproductive History and
Later-Life Comorbidity Trajectories: A Medicare-Linked Cohort Study From the Utah
Population Database. Demography 52:2021-49. PMCID: PMC4655204
Inter
Col.
Intra
Col.
9.
Hashibe M (CCPS), Galeone C, Buys SS (CCPS), Gren L, Boffetta P, Zhang ZF, La
Vecchia C (2015) Coffee, tea, caffeine intake, and the risk of cancer in the PLCO
cohort. Br J Cancer 113:809-16. PMCID: PMC4559834
10.
Huang YH, Zhang ZF, Tashkin DP, Feng B, Straif K, Hashibe M (CCPS) (2015) An
epidemiologic review of marijuana and cancer: an update. Cancer Epidemiol
Biomarkers Prev 24:15-31. PMCID: PMC4302404
11.
Hung RJ, Ulrich CM (CCPS), Goode EL, Brhane Y, Muir K, Chan AT, Marchand LL,
Schildkraut J, Witte JS, Eeles R, Boffetta P, Spitz MR, Poirier JG, Rider DN, Fridley
BL, Chen Z, Haiman C, Schumacher F, Easton DF, Landi MT, Brennan P, Houlston
R, Christiani DC, Field JK, Bickeböller H, Risch A, Kote-Jarai Z, Wiklund F, Grönberg
H, Chanock S, Berndt SI, Kraft P, Lindström S, Al Olama AA, Song H, Phelan C,
Wentzensen N, Peters U, Slattery ML (CCPS), Sellers TA, Casey G, Gruber SB,
Hunter DJ, Amos CI, Henderson B (2015) Cross Cancer Genomic Investigation of
Inflammation Pathway for Five Common Cancers: Lung, Ovary, Prostate, Breast, and
Colorectal Cancer. J Natl Cancer Inst 107. PMCID: PMC4675100
12.
Kaphingst KA (CCPS), Ivanovich J, Biesecker BB, Dresser R, Seo J, Dressler LG,
Goodfellow PJ, Goodman MS (2016) Preferences for return of incidental findings from
genome sequencing among women diagnosed with breast cancer at a young age.
Clin Genet 89:378-84
13.
Kepka D (CCPS), Ding Q, Bodson J, Warner EL, Mooney K (CCPS) (2015) Latino
Parents' Awareness and Receipt of the HPV Vaccine for Sons and Daughters in a
State with Low Three-Dose Completion. J Cancer Educ 30:808-12
14.
Kepka D (CCPS), Warner EL, Kinney AY, Spigarelli MG, Mooney K (CCPS) (2015)
Low human papillomavirus (HPV) vaccine knowledge among Latino parents in Utah. J
Immigr Minor Health 17:125-31
15.
Kirchhoff AC (CCPS), Parsons HM, Kuhlthau KA, Leisenring W, Donelan K, Warner
EL, Armstrong GT, Robison LL, Oeffinger KC, Park ER (2015) Supplemental security
income and social security disability insurance coverage among long-term childhood
cancer survivors. J Natl Cancer Inst 107:djv057. PMCID: PMC4650970
16.
Kuchenbaecker KB, Ramus SJ, Tyrer J, Lee A (CCPS), Shen HC, Beesley J,
Lawrenson K, McGuffog L, Healey S, Lee JM, Spindler TJ, Lin YG, Pejovic T, Bean Y,
Li Q, Coetzee S, Hazelett D, Miron A, Southey M, Terry MB, Goldgar DE (CCPS),
Buys SS (CCPS), Janavicius R, Dorfling CM, van Rensburg EJ, Neuhausen SL, Ding
YC, Hansen TV, Jønson L, Gerdes AM, Ejlertsen B, Barrowdale D, Dennis J, Benitez
J, Osorio A, Garcia MJ, Komenaka I, Weitzel JN, Ganschow P, Peterlongo P, Bernard
L, Viel A, Bonanni B, Peissel B, Manoukian S, Radice P, Papi L, Ottini L, Fostira F,
Konstantopoulou I, Garber J, Frost D, Perkins J, Platte R, Ellis S, Godwin AK,
Schmutzler RK, Meindl A, Engel C, Sutter C, Sinilnikova OM, Damiola F, Mazoyer S,
Stoppa-Lyonnet D, Claes K, De Leeneer K, Kirk J, Rodriguez GC, Piedmonte M,
O'Malley DM, de la Hoya M, Caldes T, Aittomäki K, Nevanlinna H, Collée JM, Rookus
MA, Oosterwijk JC, Tihomirova L, Tung N, Hamann U, Isaccs C, Tischkowitz M,
Imyanitov EN, Caligo MA, Campbell IG, Hogervorst FB, Olah E, Diez O, Blanco I,
Brunet J, Lazaro C, Pujana MA, Jakubowska A, Gronwald J, Lubinski J, Sukiennicki
G, Barkardottir RB, Plante M, Simard J, Soucy P, Montagna M, Tognazzo S, Teixeira
MR, Pankratz VS, Wang X, Lindor N, Szabo CI, Kauff N, Vijai J, Aghajanian CA,
Pfeiler G, Berger A, Singer CF, Tea MK, Phelan CM, Greene MH, Mai PL, Rennert G,
Mulligan AM, Tchatchou S, Andrulis IL, Glendon G, Toland AE, Jensen UB, Kruse TA,
Thomassen M, Bojesen A, Zidan J, Friedman E, Laitman Y, Soller M, Liljegren A,
Arver B, Einbeigi Z, Stenmark-Askmalm M, Olopade OI, Nussbaum RL, Rebbeck TR,
Nathanson KL, Domchek SM, Lu KH, Karlan BY, Walsh C, Lester J, Hein A, Ekici AB,
Beckmann MW, Fasching PA, Lambrechts D, Van Nieuwenhuysen E, Vergote I,
Lambrechts S, Dicks E, Doherty JA, Wicklund KG, Rossing MA, Rudolph A, ChangClaude J, Wang-Gohrke S, Eilber U, Moysich KB, Odunsi K, Sucheston L, Lele S,
Wilkens LR, Goodman MT, Thompson PJ, Shvetsov YB, Runnebaum IB, Dürst M,
Hillemanns P, Dörk T, Antonenkova N, Bogdanova N, Leminen A, Pelttari LM, Butzow
R, Modugno F, Kelley JL, Edwards RP, Ness RB, du Bois A, Heitz F, Schwaab I,
Harter P, Matsuo K, Hosono S, Orsulic S, Jensen A, Kjaer SK, Hogdall E, Hasmad
HN, Azmi MA, Teo SH, Woo YL, Fridley BL, Goode EL, Cunningham JM, Vierkant
RA, Bruinsma F, Giles GG, Liang D, Hildebrandt MA, Wu X, Levine DA, Bisogna M,
Berchuck A, Iversen ES, Schildkraut JM, Concannon P, Weber RP, Cramer DW,
Terry KL, Poole EM, Tworoger SS, Bandera EV, Orlow I, Olson SH, Krakstad C,
Salvesen HB, Tangen IL, Bjorge L, van Altena AM, Aben KK, Kiemeney LA,
Massuger LF, Kellar M, Brooks-Wilson A, Kelemen LE, Cook LS, Le ND, Cybulski C,
Yang H, Lissowska J, Brinton LA, Wentzensen N, Hogdall C, Lundvall L, Nedergaard
L, Baker H, Song H, Eccles D, McNeish I, Paul J, Carty K, Siddiqui N, Glasspool R,
Whittemore AS, Rothstein JH, McGuire V, Sieh W, Ji BT, Zheng W, Shu XO, Gao YT,
Rosen B, Risch HA, McLaughlin JR, Narod SA, Monteiro AN, Chen A, Lin HY,
Permuth-Wey J, Sellers TA, Tsai YY, Chen Z, Ziogas A, Anton-Culver H, GentryMaharaj A, Menon U, Harrington P, Lee AW (CCPS), Wu AH, Pearce CL, Coetzee G,
Pike MC, Dansonka-Mieszkowska A, Timorek A, Rzepecka IK, Kupryjanczyk J,
Freedman M, Noushmehr H, Easton DF, Offit K, Couch FJ, Gayther S, Pharoah PP,
Antoniou AC, Chenevix-Trench G (2015) Identification of six new susceptibility loci for
invasive epithelial ovarian cancer. Nat Genet 47:164-71. PMCID: PMC4445140
17.
Kwan ML, Bernard PS (ET), Kroenke CH, Factor RE (CRR), Habel LA, Weltzien EK,
Castillo A, Gunderson EP, Maxfield KS, Stijleman IJ, Langholz BM, Quesenberry CP,
Kushi LH, Sweeney C (CCPS), Caan BJ (2015) Breastfeeding, PAM50 tumor
subtype, and breast cancer prognosis and survival.JNatlCancerInst107. PMCID:
PMC4554253
18.
Nan H, Hutter CM, Lin Y, Jacobs EJ, Ulrich CM, White E, Baron JA, Berndt SI,
Brenner H, Butterbach K, Caan BJ, Campbell PT, Carlson CS, Casey G, ChangClaude J, Chanock SJ, Cotterchio M, Duggan D, Figueiredo JC, Fuchs CS,
Giovannucci EL, Gong J, Haile RW, Harrison TA, Hayes RB, Hoffmeister M, Hopper
JL, Hudson TJ, Jenkins MA, Jiao S, Lindor NM, Lemire M, Le Marchand L, Newcomb
PA, Ogino S, Pflugeisen BM, Potter JD, Qu C, Rosse SA, Rudolph A, Schoen RE,
Schumacher FR, Seminara D, Slattery ML (CCPS), Thibodeau SN, Thomas F,
Thornquist M, Warnick GS, Zanke BW, Gauderman WJ, Peters U, Hsu L, Chan AT
(2015) Association of aspirin and NSAID use with risk of colorectal cancer according
to genetic variants. JAMA 313:1133-42. PMCID: PMC4382867
19.
Neklason DW (CCPS), VanDerslice J, Curtin K (CCPS), Cannon-Albright LA
(CCPS) (2016) Evidence for a heritable contribution to neuroendocrine tumors of the
small intestine. Endocr Relat Cancer 23:93-100. PMCID: PMC4684974
20.
Reblin M, Clayton MF (CCPS), John KK, Ellington L (CCPS) (2015) Addressing
Methodological Challenges in Large Communication Data Sets: Collecting and
Coding Longitudinal Interactions in Home Hospice Cancer Care. Health Commun 1-9
21.
Reblin M, Cloyes KG, Carpenter J, Berry PH, Clayton MF (CCPS), Ellington L
(CCPS) (2015) Social support needs: discordance between home hospice nurses and
former family caregivers. Palliat Support Care 13:465-72
22.
Samadder NJ (CCPS), Curtin K (CCPS), Pappas L, Boucher K (CCPS), Mineau
GP (CCPS), Smith K (CCPS), Fraser A, Wan Y, Provenzale D, Kinney AY, Ulrich C
(CCPS), Burt RW (CCPS) (2016) Risk of incident colorectal cancer and death after
Colonoscopy: A population-based study in Utah. Clin Gastroenterol Hepatol 14:279286.e2
23.
Terry MB, Phillips KA, Daly MB, John EM, Andrulis IL, Buys SS (CCPS), Goldgar DE
(CCPS), Knight JA, Whittemore AS, Chung WK, Apicella C, Hopper JL (2015) Cohort
Profile: The Breast Cancer Prospective Family Study Cohort (ProF-SC). Int J
Epidemiol
24.
Wu YP (CCPS), Aspinwall LG (CCPS), Michaelis TC, Stump T, Kohlmann WG,
Leachman SA (CCPS) (2016) Discussion of photoprotection, screening, and risk
behaviors with children and grandchildren after melanoma genetic testing. J
Community Genet 7:21-31. PMCID: PMC4715817